We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies. In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
RZLT Shares Rise 30.8% in 6 Months: What's Driving the Rally?
Read MoreHide Full Article
Shares of Rezolute (RZLT - Free Report) have rallied 30.8% in the past six months against the industry’s decline of 4.1%, driven by investor enthusiasm about the company’s encouraging progress with the development activities for its lead pipeline candidate, ersodetug (RZ358).
Rezolute is a late-stage clinical biotech focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI).
The company is evaluating ersodetug in the phase III sunRIZE study for treating patients with congenital HI, an ultra-rare pediatric genetic disorder.
Factors Driving RZLT Stock Price
Image Source: Zacks Investment Research
Earlier this week, the company announced outcomes from the open label arm (OLA) portion of the phase III sunRIZE study.
An independent Data Monitoring Committee (DMC) reviewed the OLA of the sunRIZE study, which evaluated ersodetug in eight infants aged between three months to one year for treating congenital HI. Per the DMC review, treatment with ersodetug was generally safe and well-tolerated in the given patient population. The DMC also approved the enrollment of subsequent infants into the double-blind portion of the study.
Enrollment of participants in the sunRIZE study is expected to be completed in the second quarter of 2025, with top-line data anticipated in the fourth quarter of 2025.
The FDA granted a Breakthrough Therapy designation to ersodetug for the treatment of hypoglycemia due to congenital HI in January 2025.
The FDA removed the partial clinical hold on the phase III sunRIZE study evaluating ersodetug in patients with congenital HI in September 2024.
RZLT Developing Ersodetug in Tumor HI Too
Besides congenital HI, Rezolute is also developing ersodetug for the treatment of hypoglycemia caused by tumor HI, a rare disease.
The company is currently gearing up for start-up activities for the phase III registrational study evaluating ersodetug in patients with tumor HI. Enrollment of patients in the study is expected to begin later in the first half of 2025. Top-line data from the same is expected in the second half of 2026.
The FDA granted an Orphan Drug designation to ersodetug for treating hypoglycemia caused by tumor HI in December 2024.
In August 2024, the FDA cleared Rezolute’s investigational new drug application for ersodetug for treating hypoglycemia in patients with tumor HI.
The successful development of ersodetug, with some clinical milestones expected later in the year, should continue the upward momentum for the stock in 2025.
In the past 60 days, estimates for Harmony Biosciences’ earnings per share have increased from $2.64 to $3.22 for 2025. In the past year, shares of HRMY have rallied 23.4%.
HRMY’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 147.24%.
In the past 60 days, estimates for Castle Biosciences’ 2025 loss per share have narrowed from $1.84 to $1.70. In the past year, shares of CSTL have increased 19.8%.
CSTL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%.
In the past 60 days, estimates for BioMarin’s earnings per share have moved up from $3.94 to $4.01 for 2025. In the past year, shares of BMRN have plunged 28.4%.
BMRN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 28.70%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
RZLT Shares Rise 30.8% in 6 Months: What's Driving the Rally?
Shares of Rezolute (RZLT - Free Report) have rallied 30.8% in the past six months against the industry’s decline of 4.1%, driven by investor enthusiasm about the company’s encouraging progress with the development activities for its lead pipeline candidate, ersodetug (RZ358).
Rezolute is a late-stage clinical biotech focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI).
The company is evaluating ersodetug in the phase III sunRIZE study for treating patients with congenital HI, an ultra-rare pediatric genetic disorder.
Factors Driving RZLT Stock Price
Image Source: Zacks Investment Research
Earlier this week, the company announced outcomes from the open label arm (OLA) portion of the phase III sunRIZE study.
An independent Data Monitoring Committee (DMC) reviewed the OLA of the sunRIZE study, which evaluated ersodetug in eight infants aged between three months to one year for treating congenital HI. Per the DMC review, treatment with ersodetug was generally safe and well-tolerated in the given patient population. The DMC also approved the enrollment of subsequent infants into the double-blind portion of the study.
Enrollment of participants in the sunRIZE study is expected to be completed in the second quarter of 2025, with top-line data anticipated in the fourth quarter of 2025.
The FDA granted a Breakthrough Therapy designation to ersodetug for the treatment of hypoglycemia due to congenital HI in January 2025.
The FDA removed the partial clinical hold on the phase III sunRIZE study evaluating ersodetug in patients with congenital HI in September 2024.
RZLT Developing Ersodetug in Tumor HI Too
Besides congenital HI, Rezolute is also developing ersodetug for the treatment of hypoglycemia caused by tumor HI, a rare disease.
The company is currently gearing up for start-up activities for the phase III registrational study evaluating ersodetug in patients with tumor HI. Enrollment of patients in the study is expected to begin later in the first half of 2025. Top-line data from the same is expected in the second half of 2026.
The FDA granted an Orphan Drug designation to ersodetug for treating hypoglycemia caused by tumor HI in December 2024.
In August 2024, the FDA cleared Rezolute’s investigational new drug application for ersodetug for treating hypoglycemia in patients with tumor HI.
The successful development of ersodetug, with some clinical milestones expected later in the year, should continue the upward momentum for the stock in 2025.
Rezolute, Inc. Price
Rezolute, Inc. price | Rezolute, Inc. Quote
RZLT's Zacks Rank & Stocks to Consider
Rezolute currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Harmony Biosciences Holdings, Inc. (HRMY - Free Report) , Castle Biosciences, Inc. (CSTL - Free Report) and BioMarin Pharmaceutical Inc. (BMRN - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Harmony Biosciences’ earnings per share have increased from $2.64 to $3.22 for 2025. In the past year, shares of HRMY have rallied 23.4%.
HRMY’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 147.24%.
In the past 60 days, estimates for Castle Biosciences’ 2025 loss per share have narrowed from $1.84 to $1.70. In the past year, shares of CSTL have increased 19.8%.
CSTL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%.
In the past 60 days, estimates for BioMarin’s earnings per share have moved up from $3.94 to $4.01 for 2025. In the past year, shares of BMRN have plunged 28.4%.
BMRN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 28.70%.